<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28249">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02738970</url>
  </required_header>
  <id_info>
    <org_study_id>BO30185</org_study_id>
    <nct_id>NCT02738970</nct_id>
  </id_info>
  <brief_title>A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Early Breast Cancer (EBC)</brief_title>
  <official_title>A Phase I, Open-Label, Two-Part, Multicenter Perjeta Subcutaneous Dose-Finding Study in Combination With Herceptin in Healthy Male Volunteers and Female Patients With Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study involves a two-part design. Part 1 is designed to determine the optimal dose of
      subcutaneous (SC) Perjeta, injected alone or mixed with Herceptin, that results in
      comparable exposure to intravenous (IV) Perjeta. Exposure between SC Perjeta and IV Perjeta
      will be compared using a compilation of pharmacokinetic (PK) parameters such as area under
      the concentration-time curve (AUC), maximum serum concentration (Cmax), time of maximum
      concentration (Tmax), and serum trough concentration (Ctrough). Part 2 is designed to
      confirm the dosing regimen in women with EBC on the basis of safety, tolerability, and PK
      assessments.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2016</start_date>
  <completion_date type="Anticipated">August 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SC Perjeta Loading Dosage (in Milligrams) that Results in Comparable Exposure to IV Perjeta (When SC Perjeta is Mixed with Herceptin SC and Given as a Single Injection) as Assessed by a Compilation of PK Parameters (AUC, Cmax, Tmax, Ctrough)</measure>
    <time_frame>PK sampling pre-dose (0 hours) and post-dose (1.5, 3, 6, 8, 12 hours) on Day 1; on Days 2, 3, 5, 8, 10, 15, 22, 35, 43, 85; and at follow-up (up to approximately 11 months overall)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SC Perjeta Maintenance Dosage (in Milligrams) that Results in Comparable Exposure to IV Perjeta (When SC Perjeta is Mixed with Herceptin SC and Given as a Single Injection) as Assessed by a Compilation of PK Parameters (AUC, Cmax, Tmax, Ctrough)</measure>
    <time_frame>PK sampling pre-dose (0 hours) and post-dose (1.5, 3, 6, 8, 12 hours) on Day 1; on Days 2, 3, 5, 8, 10, 15, 22, 35, 43, 85; and at follow-up (up to approximately 11 months overall)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SC Perjeta Loading Dosage (in Milligrams) that Results in Comparable Exposure to IV Perjeta (When SC Perjeta is Given as Single-Agent Injection) as Assessed by a Compilation of PK Parameters (AUC, Cmax, Tmax, Ctrough)</measure>
    <time_frame>PK sampling pre-dose (0 hours) and post-dose (1.5, 3, 6, 8, 12 hours) on Day 1; on Days 2, 3, 5, 8, 10, 15, 22, 35, 43, 85; and at follow-up (up to approximately 11 months overall)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SC Perjeta Maintenance Dosage (in Milligrams) that Results in Comparable Exposure to IV Perjeta (When SC Perjeta is Given as Single-Agent Injection) as Assessed by a Compilation of PK Parameters (AUC, Cmax, Tmax, Ctrough)</measure>
    <time_frame>PK sampling pre-dose (0 hours) and post-dose (1.5, 3, 6, 8, 12 hours) on Day 1; on Days 2, 3, 5, 8, 10, 15, 22, 35, 43, 85; and at follow-up (up to approximately 11 months overall)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>Continuously from Screening to 7 months post-dose (up to approximately 11 months overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) to Any Study Drug</measure>
    <time_frame>Baseline, Day 22, Day 85, and 7 months post-dose (up to approximately 11 months overall)</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Early Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1: IV Perjeta</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort 1 will include healthy male volunteers from Part 1. A single, 420-milligram (mg) IV injection of Perjeta will be administered for use as a control against Cohorts 2, 3, and 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: SC Perjeta 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2 will include healthy male volunteers from Part 1. A single, 400-mg SC injection of Perjeta will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: SC Perjeta 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3 will include healthy male volunteers from Part 1. A single, 600-mg SC injection of Perjeta will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: SC Perjeta 1200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4 will include healthy male volunteers from Part 1. A single, 1200-mg SC injection of Perjeta will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: SC Herceptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort 5 will include healthy male volunteers from Part 1. A single, 600-mg SC injection of Herceptin will be administered for use as a control against Cohorts 6, 7, and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: SC Perjeta 400 mg + SC Herceptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 6 will include healthy male volunteers from Part 1. A single, mixed SC injection containing 400 mg Perjeta and 600 mg Herceptin will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7: SC Perjeta 1200 mg + SC Herceptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 7 will include healthy male volunteers from Part 1. A single, mixed SC injection containing 1200 mg Perjeta and 600 mg Herceptin will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8: SC Perjeta 1200 mg (Without rHuPH20) + SC Herceptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 8 will include healthy male volunteers from Part 1. A single, mixed SC injection containing 1200 mg Perjeta (formulated without recombinant human hyaluronidase [rHuPH20] as an excipient) and 600 mg Herceptin will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A: SC Perjeta + SC Herceptin (Separate Injections)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A will include females with EBC in Part 2. Two separate SC injections with Perjeta and 600 mg Herceptin will be consecutively administered. The dose of Perjeta will be determined using data from Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: SC Perjeta + SC Herceptin (Mixed Injection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B will include females with EBC in Part 2. A single, mixed SC injection containing Perjeta and 600 mg Herceptin will be administered. The dose of Perjeta will be determined using data from Part 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin</intervention_name>
    <description>Herceptin will be administered separately or mixed with Perjeta, depending upon cohort, as a single SC injection of 600 mg.</description>
    <arm_group_label>Cohort 5: SC Herceptin</arm_group_label>
    <arm_group_label>Cohort 6: SC Perjeta 400 mg + SC Herceptin</arm_group_label>
    <arm_group_label>Cohort 7: SC Perjeta 1200 mg + SC Herceptin</arm_group_label>
    <arm_group_label>Cohort 8: SC Perjeta 1200 mg (Without rHuPH20) + SC Herceptin</arm_group_label>
    <arm_group_label>Cohort A: SC Perjeta + SC Herceptin (Separate Injections)</arm_group_label>
    <arm_group_label>Cohort B: SC Perjeta + SC Herceptin (Mixed Injection)</arm_group_label>
    <other_name>Trastuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perjeta</intervention_name>
    <description>Perjeta will be administered separately or mixed with Herceptin, depending upon cohort, as a single IV or SC injection. The dose will range from 400 to 1200 mg.</description>
    <arm_group_label>Cohort 1: IV Perjeta</arm_group_label>
    <arm_group_label>Cohort 2: SC Perjeta 400 mg</arm_group_label>
    <arm_group_label>Cohort 3: SC Perjeta 600 mg</arm_group_label>
    <arm_group_label>Cohort 4: SC Perjeta 1200 mg</arm_group_label>
    <arm_group_label>Cohort 6: SC Perjeta 400 mg + SC Herceptin</arm_group_label>
    <arm_group_label>Cohort 7: SC Perjeta 1200 mg + SC Herceptin</arm_group_label>
    <arm_group_label>Cohort 8: SC Perjeta 1200 mg (Without rHuPH20) + SC Herceptin</arm_group_label>
    <arm_group_label>Cohort A: SC Perjeta + SC Herceptin (Separate Injections)</arm_group_label>
    <arm_group_label>Cohort B: SC Perjeta + SC Herceptin (Mixed Injection)</arm_group_label>
    <other_name>Pertuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part 1: Healthy male volunteers 18 to 45 years of age

          -  Part 1: Left ventricular ejection fraction (LVEF) at least 55 percent (%)

          -  Part 1: Body mass index (BMI) 18 to 32 kilograms per meter-squared (kg/m^2)

          -  Part 1: Normal, intact skin without tattoos or lesions in the injection area

          -  Part 2: Females at least 18 years of age

          -  Part 2: Eastern Cooperative Oncology Group (ECOG) performance status of 0

          -  Part 2: Previously treated, non-metastatic carcinoma of the breast

          -  Part 2: Baseline LVEF at least 55%

          -  Part 2: Negative pregnancy test and use of adequate contraceptive measures among
             women of childbearing potential

        Exclusion Criteria:

          -  Part 1: Positive urine test for drugs of abuse

          -  Part 1: Hepatitis B or C, or human immunodeficiency virus (HIV)

          -  Part 1: Cardiac disease including hypertension or hypotension

          -  Part 1: Lower extremity edema

          -  Part 1: Any clinically relevant history of systemic disease

          -  Part 1: History of breast cancer

          -  Part 1: Chronic corticosteroid use

          -  Part 1: Receipt of IV antibiotics within 7 days prior to enrollment

          -  Part 2: Concurrent malignancy requiring therapy that may interfere with
             pharmacokinetic investigations, or history of other malignancy within 5 years prior
             to Screening

          -  Part 2: Significant cumulative exposure to anthracyclines

          -  Part 2: Serious cardiac disease including uncontrolled hypertension

          -  Part 2: Poor hematologic, renal, or hepatic function

          -  Part 2: Pregnant or lactating women

          -  Part 2: Hepatitis B or C, or HIV

          -  Part 2: Chronic corticosteroid use

          -  Part 2: Receipt of IV antibiotics within 7 days prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BO30185 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christchurch Clinical Studies Trust</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 10, 2017</lastchanged_date>
  <firstreceived_date>March 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
